Anti-Xa Therapy to Lower cardiovascular events in addition to Aspirin with or without thienopyridine therapy in Subjects with Acute Coronary Syndrome–Thrombolysis In Myocardial Infarction 46 - ATLAS ACS-TIMI 46


Despite percutaneous coronary intervention (PCI) and dual antiplatelet therapy, death or myocardial infarction (MI) at 1 year remain high in patients presenting with acute coronary syndromes (ACS). Oral anticoagulant therapy remains an unmet need in these patients. This was a phase II trial designed to identify tolerable doses of rivaroxaban, an oral direct factor Xa inhibitor, in the treatment of patients with ACS.